CING - Cingulate completes Phase 3 adult study for ADHD drug candidate

2023-06-08 15:27:26 ET

Cingulate ( NASDAQ: CING ) said it has completed a Phase 3 study for its drug candidate CTx-1301 in the treatment of ADHD in adults and has slated the initiation of a pivotal Phase 3 pediatric study to begin in Q3.

Cingulate expects to receive results from the Phase 3 trial for adults in Q3. If results from the Phase 3 studies are positive, the company hopes to file for US regulatory approval for the drug in mid-2004.

CTx-1301, also known as dexmethylphenidate, is a once-daily treatment for attention deficit/hyperactivity disorder, or ADHD. Cingulate said it believes the drug addresses an unmet need in the ADHD market by offering improved onset and duration.

More on Cingulate:

Cingulate Inc. SEC Filing - Quarterly Report (10-Q) May 10, 2023

Cingulate files with SEC for stock, warrants offering; inks commercialization pact for ADHD drug

Cingulate pops ~76% after hours on trial results for its ADHD treatment drug

For further details see: